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Introduction
Helicobacter pylori infection is the major cause of 
chronic gastritis, peptic ulcers, gastric mucosa-
associated lymphoid tissue lymphoma (MALT) 
and gastric cancer. Its worldwide prevalence 
approaches 50% [McColl, 2010].
The standard triple therapy combining amoxicil-
lin (1 g b.d.) and clarithromycin (500 mg b.d.) or 
metronidazole (500 mg b.d.) has long been the 
recommended first-line therapy for H. pylori 
infection [Malfertheiner et  al. 2012]. However, 
this combination seems to have lost efficacy over 
the last decade [Malfertheiner et al. 2012], mostly 
due to clarithromycin resistance [Neri et  al. 
2003]. The overall clarithromycin resistance rate 
in Europe increased from 9% in 1998 to 17.6% in 
2008 [Malfertheiner et  al. 2012], and primary 
resistances are above 20% in many European 
countries [Megraud et al. 2013].
The Maastricht IV/Florence consensus 
[Malfertheiner et  al. 2012] suggests that culture 
and standard susceptibility testing should be con-
sidered in all regions before second-line treatment 
if endoscopy is carried out for another reason (evi-
dence level: 5; grade of recommendation: D). 
However, challenging this expert opinion, a recent 
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Background: Susceptibility-guided therapies (SGTs) have been proposed as preferable 
to empirical rescue treatments after two treatment failures. The aim of this study was to 
perform a systematic review and meta-analysis evaluating the effectiveness and efficacy of 
SGT as third-line therapy.
Methods: A systematic search was performed in multiple databases. Studies reporting cure 
rates of Helicobacter pylori with SGT in third-line therapy were selected. A qualitative analysis 
describing the current evidence and a pooled mean analysis summarizing the cure rates of 
SGT in third-line therapy was performed.
Results: No randomized controlled trials or comparative studies were found. Four 
observational studies reported cure rates with SGT in third-line treatment, and three studies 
which mixed patients with second- and third-line treatment also reported cure rates with SGT. 
The majority of the studies included the patients when culture had been already obtained, and 
so the effectiveness of SGT and empirical therapy has never been compared. A pooled mean 
analysis including four observational studies (283 patients) showed intention-to-treat and per-
protocol eradication rates with SGT of 72% (95% confidence interval 56–87%; I2: 92%) and 80% 
(95% confidence interval 71–90%; I2: 80%), respectively.
Conclusions: SGT may be an acceptable option as rescue treatment. However, cure rates are, 
at best, moderate and this approach has never been compared with a well-devised empirical 
therapy. The evidence in favor of SGT as rescue therapy is currently insufficient to recommend 
its use.
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meta-analysis of randomized controlled trials 
(RCTs) [Lopez-Gongora et  al. 2015] did 
not observe significant differences between 
susceptibility-guided therapies (SGT) and empir-
ical therapy as second-line treatment in the few 
comparative studies performed. Furthermore, the 
studies included in the meta-analyses did not 
compare SGT versus the currently recommended 
quadruple therapies, and allocated patients once 
the endoscopy and culture was performed. 
Whether the need for invasive testing reduces 
the acceptability and the effectiveness of SGT in 
clinical practice remains uncertain. Finally, the 
evidence regarding SGT in third-line treatment 
has not been systematically revised to date.
The aim of this study was to perform a systematic 
review and meta-analysis evaluating the evidence 
of the efficacy of SGT in the treatment of H. 
pylori after two failed attempts.
Material and methods
The study was performed in accordance with the 
MOOSE Statement [Stroup et al. 2000], because 
the systematic review and meta-analysis included 
observational studies. The MOOSE checklist is 
shown in the online Supplementary Table 1. A 
flow-chart of the studies included in the meta-
analyses is shown in Figure 1.
Search strategy
A systematic computerized literature search was 
conducted in PubMed, Scopus, the Cochrane 
Library and the ISI Web of Knowledge including 
full-text published articles and abstracts from the 
of DDW, UEGW, EHSG and other relevant 
meetings from 1984 to May 2015. Combinations 
of different terms combinations are shown in the 
online Supplementary Table 2. In addition, refer-
ences of articles retrieved and significant reviews 
were also examined, searching for articles to 
include in the present study. Finally, the personal 
databases of the authors were also reviewed for 
eligible publications.
Inclusion criteria
We included published full-text articles that ful-
filled the following criteria: (a) they reported clin-
ical trials, observational series or comparative 
cohort studies that evaluated the H. pylori eradi-
cation rates in adult patients who received SGT; 
(b) SGT was used as rescue treatment after two 
failed attempts; (c) pretreatment diagnostic tests 
for H. pylori detection comprised one or more of 
the common validated tests [urea breath test, his-
tology, rapid urease test, stool antigen, polymer-
ase chain reaction (PCR) or culture]; (d) all of 
these tests (except culture) were considered ade-
quate as control tests; (e) control diagnostic tests 
were performed at least 4 weeks after the end of 
the eradication schedule in the absence of proton 
pump inhibitor (PPI) use. No language limita-
tions were imposed.
Data extraction
Data were extracted independently by four review-
ers (SL, VG, MB and IP) and revised by a fifth 
investigator (AV). Discordances were resolved 
by consensus with an additional investigator 
(XC). Data extraction was standardized using a 
data extraction table. Variables compiled were: 
(a) number of patients; (b) type of study (RCT, 
quasi-RCT, comparative non-RCT, noncompar-
ative); (c) method used to determine antibiotic 
susceptibility; (d) percentage of successful cul-
tures; (e) time of randomization (before or after 
endoscopy); (f) intention to treat (ITT) and (g) per-
protocol (PP) cure rates and their 95% confidence 
intervals (CIs) for the susceptibility-guided treat-
ment group; and for the control empiric treatment 
group when available (h) adherence to treatment 
and (i) number and severity of side effects.
Risk of bias
Risk of bias was assessed independently by three 
reviewers (IP, SLG and MB). Discrepancies in the 
interpretation were resolved with a third reviewer 
(XC). Observational studies were assessed follow-
ing the suggestions of Methods Guide for Effectiveness 
and Comparative Effectiveness Reviews [Agency for 
Healthcare Research and Quality, 2014]. We 
recorded whether the study was labeled as pro-
spective, the completeness of outcome data, the 
presence of selective reporting and the validity of 
pre- and post-treatment eradication tests.
Statistical analysis
The primary endpoint for the different meta-anal-
yses was the ITT efficacy. Secondary endpoints 
were PP efficacy, adherence and adverse events.
As the number of comparative studies (either ran-
domized or observational) available in third-line 
treatments was insufficient, the mean eradication 
y digestivas (CIBERehd), 
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Records identified through 
database searching
(n = 1155)
Sc
re
en
in
g
In
cl
ud
ed
El
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ib
ili
ty
Id
en
tif
ic
at
io
n
Additional records identified 
through other sources
(n = 7)
Records after duplicates removed
(n = 541)
Records screened
(n = 541)
Records excluded
(n = 510)
Full-text articles 
assessed for eligibility 
(n = 31)
Full-text articles excluded,
16 First and second-line
1 pediatric patients
3 redundant publications
2 did not perform SGT
2 cost-effectiveness studies
(n = 24)
Studies included in 
qualitative synthesis 
(n = 7)
Studies included in 
quantitative synthesis 
(pooled mean 
analysis)
(n = 4)
Figure 1. Flow of information through the various phases of the selection of the studies.
rate of SGT was calculated by combining data 
from observational noncomparative studies and 
using the generic inverse variance method, which 
involves a weighted average of the estimated effect 
from the individual studies. The weight for each 
study is taken to be the inverse of the variance 
(one divided by the square of the standard error) 
of the estimated effect. If studies differed in terms 
of treatments administered, a random effect 
model was used. The I2 statistic was used to assess 
the heterogeneity of the studies following the rec-
ommendation of the Cochrane Collaboration’s 
Handbook for Systematic Reviews of Interventions 
[Higgins and Green, 2011], as follows: 0–40%, 
negligible heterogeneity; 40–75%, moderate het-
erogeneity; 75–100% considerable heterogeneity. 
Analyses were performed using the freeware pro-
gram Review Manager (RevMan) version 5.1 
[The Cochrane Collaboration, 2012].
Results
The original searches retrieved more than 1000 
articles. Following a review of the abstracts, 34 
articles were assessed for eligibility. No unpub-
lished abstracts were found. After careful evalua-
tion of the full texts, seven were included in the 
qualitative analysis and four in the pooled mean 
analysis (Figure 1).
Studies excluded
A total of 24 studies were finally excluded, for the 
following reasons: (a) 16 included patients receiv-
ing only first- or second-line therapy [Neri et al. 
2003; Furuta et  al. 2007; Avidan et  al. 2001; 
Biscontri et al. 2001; Cosme et al. 2013; Kawai 
et  al. 2008; Lamouliatte et  al. 2003; Lee et  al. 
2013; Marzio et  al. 2006; Miwa et  al. 2003; 
Molina-Infante et al. 2012; Romano et al. 2003; 
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Table 2. Antimicrobial therapies used in third-line therapy studies.
Study First-line 
treatment
Second-line treatment Drug resistance after 
the second treatment 
failure
Susceptibility-
guided third-line 
treatment
N Treatment 
duration
Cammarota 
et al. [2004]
PPI b.d., 
A 1 g b.d., 
M 250 mg 
q.d. or TI 
500 mg 
b.d. for 7 
days  
(n = 37)
PPI (double dose per 
day), A 1 g, C 250 or 
500 mg b.d. for 7 days 
(n = 27)
PPI (double dose per 
day), A 1 g, L 500 mg 
b.d. for 7 days (n = 7)
O 20 mg b.d., B 120 
mg q.d.s., A 1 g b.d., 
TE 500 mg q.d.s. for 7 
days (n = 3)
M: 100%
C: 95%
L: 31%
TE: 5%
A: 0%
A and TE 
sensitive:
B 120 mg q.d,s., 
O 20 mg b.d., A 1 
g b.d., D 100 mg 
b.d.
89 7 days
PPI, A 1 
g, C 250 
or 500 mg 
b.d. for 7 
days  
(n = 34)
PPI (double dose per 
day), B 120 mg q.d.s., 
M 250 mg q.d.s or TI 
500 mg b.d., TE 500 
mg q.d.s. for 7 days (n 
= 28)
PPI (double dose per 
day), A 1 g, L 500 mg 
b.d. for 7 days (n = 6)
TE, M and C 
resistant:
O 20 mg b.d., A 1 
g b.d., L 500 mg 
b.d.
4 7 days
PPI b.d., A 
1 g, L 500 
mg b.d. for 
7 days (n 
= 23)
PPI (double dose per 
day), A 1 g, C 250 or 
500 mg b.d. for 7 days 
(n = 11)
O 20 mg b.d., B 120 
mg q.d.s., A 1 g b.d., 
TE 500 mg q.d.s. for 7 
days (n = 2)
PPI (double dose per 
day), B 120 mg q.d.s., 
M 250 mg q.d.s or TI 
500 mg b.d., TE (500 
mg q.d.s for 7 days  
(n = 10)
TE, M and L 
resistant:
O 20 mg, A 1 g, C 
500 mg b.d.
1 7 days
Gasbarrini 
et al. [2000]
PPI, TI, C 7 
days  
(n = 58)
RBC, A C 7 days (n = 
58)
AZ: 68%
ER: 62%
C: 56%
M and TI 56%
TE 12%
A 0%
PPI, B, A, TE 26 Not reported
PPI, B, A, M 9
PPI, B, TE, M 4
Liou et al. 
[2013]
100% (131/131) received C and 79.1% 
(102/129) L in first or in second line
23S rRNA mutation 
(tissue) 78.9% 
(101/128)
23S rRNA mutation 
(strain) 85.7% (84/98)
Gyrase A mutation 
(tissue) 41.3% 
(52/126)
Gyrase A mutation 
(strain) 42.9% (42/98)
L resistance 46.9% 
(45/96)
A resistance 9.4% 
(9/96)
M resistance 58.3% 
(56/96)
TE resistance 3.2% 
(3/93)
C resistance 86.5% 
(83/96)
23S rRNA wild-
type:
ES 40 mg, A 1 g, 
M 500 mg, C 500 
mg b.d.
19 ES, A 7 days 
followed by M, 
C 7 days
23S rRNA 
mutant-type and 
gyrA wild-type:
ES 40 mg, A 1 g, 
M 500 mg, L 250 
mg b.d.
51 ES, A 7 days 
followed by M, 
LE 7 days
23S rRNA 
mutant-type and 
gyrA mutant-type:
ES 40 mg, A 1 g, 
M 500 mg, TE 500 
mg b.d.
65 ES, A 7 days 
followed by M, 
TE 7 days
(Continued)
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Study First-line 
treatment
Second-line treatment Drug resistance after 
the second treatment 
failure
Susceptibility-
guided third-line 
treatment
N Treatment 
duration
Vicente et al. 
[2002]
Not 
reported
Not reported M resistance 44% 
(18/41)
C resistance 52% 
(21/41)
Both C and M 
resistance 19% 
(5/41)
A 0%
TE 0%
Susceptible to C 
and M:
O 20 mg b.d., B 
120 mg q.d., TE 
500 mg q.d., C 
500 mg b.d.
9 14 days
Resistant to C:
O 20 mg b.d., B 
120 mg q.d., TE 
500 mg q.d., A 1 
g b.d.
13 14 days
Resistant to M:
O 20 mg b.d., B 
120 mg q.d., TE 
500 mg q.d., C 
500 mg b.d./ A 1 
g b.d.
10 14 days
M and C resistant 
and penicillin 
allergy:
O 20 mg b.d., B 
120 mg q.d., TE 
500 mg q.d., CI 
500 mg b.d.
8 14 days
PPI, proton pump inhibitor; A, amoxicillin; C, clarithromycin; L, levofloxacin; M, metronidazole; TI, tinidazole; b.d., twice a day; q.d.s., four times a 
day; TE, tetracycline; B, bismuth; O, omeprazole; D, doxycycline; RBC, ranitidine bismuth citrate; AZ, azithromycin; ER, erythromycin; ES, esome-
prazole; SGT, susceptibility-guided therapy.
Table 2. (Continued)
Sugimoto et  al. 2014; Toracchio et  al. 2000; 
Wang et  al. 2008; Zhou et  al. 2010]; (b) one 
included pediatric patients [Lopes et  al. 2005]; 
(b) three reported data on patients already 
included in another study [Gomollón et al. 2000; 
Furuta et al. 2005; Romano et al. 2000]; (c) two 
did not perform susceptibility-guided treatment 
[Seppala et al. 2000; Graham et al. 2000]; (d) two 
were cost-effectiveness studies [Breuer and 
Graham, 1999; Zullo et al. 2003b].
Studies included reporting cure rates of SGT in 
third-line treatment
No RCTs or studies comparing SGT versus 
empirical treatment after two H. pylori eradication 
attempts were found. Only four observational 
noncomparative studies including 283 patients 
reported the mean cure rates of SGT in third-line 
therapy [Cammarota et al. 2004; Gasbarrini et al. 
2000; Liou et  al. 2013; Vicente et  al. 2002]. In 
addition, two noncontrolled studies [Fiorini et al. 
2013; Tay et al. 2012] and one controlled nonran-
domized study [Yahav et al. 2006] reported cure 
rates of SGT mixing patients with second and 
third-line treatment. All of the studies except one 
[Gasbarrini et  al. 2000] included patients once 
endoscopy had been performed; furthermore, in 
many of them, patients were included only when a 
positive culture had been obtained. So, the effec-
tiveness and applicability of SGT in clinical prac-
tice could not be evaluated.
Table 1 shows the main characteristics of the 
studies and cure rates of SGT. Previous antibiotic 
treatment and antibiotic strategy according to sus-
ceptibility tests varied widely (Tables 2 and 3). 
The risk of bias for observational studies is sum-
marized in Figure 2. All of the studies were non-
RCTs, but were described as prospective, included 
consecutive patients, used a valid diagnostic and 
control test and reported complete data.
Cammarota and colleagues conducted a prospec-
tive study in Italy including 94 consecutive patients 
who underwent endoscopy with antral biopsies 
and in whom successful susceptibility analyses 
were obtained using the Epsilometer test (E-test) 
[Cammarota et al. 2004]. In the ITT analysis they 
did not include 14 patients who had shown poor 
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compliance with the previously prescribed regi-
mens. Four eligible patients were also excluded 
from the ITT analysis because H. pylori could not 
be cultured. First-line treatments consisted of a 
7-day triple therapy based on a PPI, amoxicillin 
and clarithromycin, levofloxacin or an imidazole. 
In second-line treatment, a 7-day bismuth quad-
ruple therapy or a different 7-day triple therapy 
was administered. In third-line treatment, H. 
pylori harbored a high prevalence of resistant 
strains (metronidazole 100%, clarithromycin 
95%, levoﬂoxacin 31%, tetracycline 5%, amoxi-
cillin 0%). A 7-day bismuth quadruple therapy 
containing amoxicillin, tetracycline and omepra-
zole was used in 89 patients. The five patients har-
boring tetracycline-resistant strains were treated 
with a 7-day triple therapy with levofloxacin or 
clarithromycin. Following this strategy, and taking 
into account the restrictive inclusion criteria 
(patients with good previous compliance, positive 
culture, etc.) and the many exclusions, they 
obtained cure rates of 90% (ITT) and 91% (PP).
In Italy, Gasbarrini and colleagues evaluated the 
efficacy of a multistep strategy for H. pylori eradi-
cation [Gasbarrini et al. 2000]. A total of 2606 H. 
pylori-positive patients were administered tinida-
zole, clarithromycin and a PPI for 1 week. A total 
of 350 patients with continuing infection were 
then given a second 1-week course of amoxicillin, 
clarithromycin and ranitidine bismuth citrate. A 
total of 58 patients still infected after the second 
course were invited to undergo an upper gastroin-
testinal endoscopy with H. pylori culture, but only 
49 accepted. Finally, H. pylori culture was obtained 
in 39 out of these 49 patients. In vitro antibiotic 
susceptibility analysis by using the E-test showed a 
high overall prevalence of poly-antibiotic-resistant 
H. pylori strains (azithromycin 68%, erythromycin 
62%, clarithromycin 56%, metronidazole and 
tinidazole 56%, tetracycline 12% and amoxicillin 
0%). They received a 1-week quadruple PPI-
bismuth-based scheme established on H. pylori 
antibiotic sensitivity, and achieved a mean eradi-
cation rate of 77% by PP analysis (30 out of 39) or 
51.7% by ITT (30 out of 58).
In Taiwan, Liou and colleagues conducted a 
study in 135 patients who underwent an upper 
endoscopy and biopsies [Liou et  al. 2013]. The 
study did not state the number of patients who 
declined endoscopy. Genotypic and phenotypic 
resistances were determined by PCR with direct 
sequencing (23S rRNA and gyrA) and agar dilu-
tion test, respectively. The authors found an 
excellent correlation between clarithromycin and 
levofloxacin phenotypic and genotypic resistance. 
The patients were re-treated with a sequential 
therapy containing esomeprazole and amoxicillin 
for the ﬁrst 7 days, followed by esomeprazole and 
metronidazole plus clarithromycin, levoﬂoxacin 
or tetracycline for another 7 days according to the 
genotypic resistance determined using gastric 
biopsy specimens. The overall eradication rate 
was 80.7% (109/135) in the ITT analysis and 
82.6% (109/132) in the PP analysis.
Vicente and colleagues included 42 patients in a 
Spanish multicenter observational study who 
failed both a 7-day triple therapy and a second-
line empirical attempt [Vicente et al. 2002]. These 
authors found a prevalence of resistance to 
clarithromycin and metronidazole around 50% 
by using the E-test and administered a 14-day 
bismuth-containing quadruple therapy. Four 
patients were not included in the PP analyses 
(one patient with culture failure, one with multi-
drug allergy, one who did not accept the treat-
ment and one more who did not attend the 
follow-up visit). H. pylori was cured in only 60% 
of infected patients despite good compliance 
Figure 2. Risk of bias of the studies included in the 
qualitative analysis.
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(>90% in all the patients included). Surprisingly, 
cure was not achieved in six out of nine patients 
infected by a H. pylori strain susceptible to all 
antibiotics. The authors suggest that, in addition 
to antibiotic resistances, unknown factors (for 
instance, host immunogenicity or differences in 
the adherence of H. pylori to the mucosa) may 
also influence treatment efficacy.
In Italy, Fiorini and colleagues included 254 
patients who failed at least one standard therapy for 
H. pylori eradication and underwent an upper 
endoscopy [Fiorini et al. 2013]. A total of 44% had 
failed at least two treatment attempts. Culture was 
obtained in 236 patients (93%) and a susceptibility 
analysis using the E-test identified 131 patients 
with levofloxacin-susceptible and 105 with levo-
floxacin-resistant strains. In patients with levofloxa-
cin-susceptible H. pylori strains, 50% were resistant 
to clarithromycin and metronidazole, 43% to 
clarithromycin alone and 8% to metronidazole 
alone. In the levofloxacin-resistant H. pylori strains, 
85% were also resistant to clarithromycin and met-
ronidazole and 8% to both clarithromycin and met-
ronidazole alone. Patients received either 10 days 
of levofloxacin or 12 days of rifabutin (in the case of 
patients resistant to levofloxacin) in combination 
with amoxicillin and esomeprazole. All patients 
took at least 90% of the prescribed drugs. H. pylori 
infection was cured in 90% of the patients who 
received levofloxacin triple therapy and 89% of the 
patients who received rifabutin triple therapy. 
Unfortunately, the results for second- and third-
line treatments were not reported separately.
In Australia, Tay and colleagues successfully cul-
tured 306 H. pylori strains from 310 consecutive 
patients who had completed and failed at least one 
course of the standard 7-day triple therapy con-
taining PPI and combinations of amoxicillin, 
clarithromycin or metronidazole [Tay et al. 2012]. 
The proportions resistant to clarithromycin and 
metronidazole using the E-test were 94.1% and 
67.6%, respectively, with 65% presenting resist-
ance to both. Resistance to ciprofloxacin and 
rifampicin was 6% and 2%, respectively. In 
patients harboring rifampicin-susceptible strains, 
10-day treatment with rabeprazole and amoxicillin 
plus rifabutin and ciprofloxacin from day 6, for 5 
days, was prescribed. This schedule obtained a 
95% cure rate. Again, the results for second- and 
third-line treatments were not reported separately.
Finally, in Israel Yahav and colleagues enrolled 
49 patients who also failed at least one treatment 
course and in whom an upper endoscopy and cul-
ture had been performed [Yahav et  al. 2006]. 
These authors compared the efficacy of SGT with 
a cohort of patients who received empirical rescue 
treatment. Resistance rates to clarithromycin and 
metronidazole by using the E-test were 59% and 
47%, respectively (29% to both antibiotics). The 
empirical treatment consisted in a 7-day triple 
therapy containing clarithromycin or metronida-
zole or a 7-day bismuth-containing quadruple 
therapy. In the experimental group, the same 
therapies were administered but depending on 
the susceptibility of the H. pylori strain. SGT was 
significantly more efficacious than empirical ther-
apy (86% versus 63%, p = 0.02).
Pooled mean analysis of cure rates of SGT as 
third-line treatment
As no RCTs or comparative observational studies 
reporting efficacy of SGT versus empirical therapy 
were found, a meta-analysis of cure rates of SGT 
of noncomparative studies was performed. ITT 
and PP analyses including four studies (283 
patients) showed mean eradication rates of 72% 
(95% CI 56–87%; I2: 92%) and 80% (95% CI 
71–90%; I2: 80%), respectively. In view of the lack 
of comparative trials and the high heterogeneity 
between the studies, this pooled mean cure rate 
should be interpreted with caution. The poorest 
results according to ITT were shown in the only 
study that reported rates of patients’ acceptance of 
upper endoscopy and the rates of positive culture. 
As these two issues were not considered in the 
ITT analysis of the remaining studies, the effec-
tiveness in clinical practice may be even lower.
Safety and side effects
Percentages of patients with adverse events were 
generally not reported. Cammarota and col-
leagues reported poor tolerance of quadruple bis-
muth therapy, and 1 out of 94 patients abandoned 
treatment due to severe side effects [Cammarota 
et al. 2004]; Liou and colleagues reported a drop-
out rate of 1% due to side effects [Liou et  al. 
2013]; and Vicente and colleagues reported no 
severe adverse events or dropouts [Vicente et al. 
2002]. Fiorini and colleagues reported mild-to-
moderate side effects in 15% and 20% of patients 
in each treatment arm; however, all patients com-
plied with at least 90% of the treatment [Fiorini 
et al. 2013]. Gasbarrini and colleagues, Tay and 
coworkers and Yahav’s group did not mention 
the number of patients with adverse events, 
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though the latter author reported a treatment 
compliance of 97% [Gasbarrini et al. 2000; Tay 
et al. 2012; Yahav et al. 2006].
Discussion
The present study highlights the lack of strong evi-
dence regarding SGT in third-line therapy, as no 
RCTs or comparative studies with empirical treat-
ment were found. The pooled mean analysis of 
cure rates including four observational noncom-
parative studies showed ITT and PP mean cure 
rates of 72% and 80%, respectively. However, the 
heterogeneity of the studies was high and this 
pooled mean cure rate should be interpreted care-
fully. Although the PP cure rate after two failed 
attempts was acceptable, ITT cure rates were not 
as good as desired. Furthermore, as three out of 
the four studies included patients once the endos-
copy and the culture was obtained, the acceptance 
of an invasive procedure and feasibility of a suc-
cessful culture was not considered. So, the effec-
tiveness in clinical practice may be even lower 
than 70%. However, if the patient accepts an inva-
sive test and a culture is feasible, SGT may be an 
acceptable strategy in third-line treatment.
This study agrees with the Maastricht consensus 
which suggested that treatment could be guided 
by antimicrobial susceptibility testing, whenever 
possible, after failure of second-line therapy (evi-
dence level: 4; grade of recommendation: A). On 
the other hand, empirical treatment after two 
failed attempts has shown heterogeneous results: 
65–85% with bismuth-containing quadruple 
therapies [Hsu et al. 2008; Gisbert et al. 2014], 
60–90% with levofloxacin-based therapy [Sereni 
et al. 2012; Tursi et al. 2012; Gisbert et al. 2006; 
Zullo et al. 2003a] and 62–95% with a rifabutin-
based therapy associated with PPIs and amoxicil-
lin [Lim et al. 2014; González et al. 2007]. The 
studies differ in terms of previously administered 
therapies, study populations and drug schedules. 
So, until comparative studies are available, SGT 
also seems to be an acceptable treatment option 
in third-line treatment.
The major strong points of the study are the 
updated systematic review, the qualitative analysis 
and the pooled mean analyses of cure rates for 
summarizing the current evidence. The quality of 
the observational studies was acceptable. However, 
major limitations are the lack of comparative analy-
ses, the high heterogeneity between the studies and 
the evaluation of acceptance of an invasive test and 
the feasibility of H. pylori culture. All of the studies 
tend to use four drugs or long therapies after antibi-
otic sensitivity testing. Therefore, it is difficult to 
ascertain whether the improved cure rates are due 
to the determination of antibiotic resistances or to 
the use of far more effective therapies. This aspect 
requires future investigation.
In conclusion, SGT may be an acceptable option 
as rescue treatment. However, cure rates are, at 
best, moderate and this approach has never been 
compared with a well-devised empirical therapy, 
particularly with the highly effective quadruple 
therapies. The evidence in favor of SGT as rescue 
therapy is currently insufficient to recommend its 
use in clinical practice.
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